首页> 美国卫生研究院文献>Bone Research >Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis
【2h】

Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis

机译:肠道菌群:治疗绝经后骨质疏松症的潜在目标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Postmenopausal osteoporosis (PMO) is a prevalent metabolic bone disease characterized by bone loss and structural destruction, which increases the risk of fracture in postmenopausal women. Owing to the high morbidity and serious complications of PMO, many efforts have been devoted to its prophylaxis and treatment. The intestinal microbiota is the complex community of microorganisms colonizing the gastrointestinal tract. Probiotics, which are dietary or medical supplements consisting of beneficial intestinal bacteria, work in concert with endogenous intestinal microorganisms to maintain host health. Recent studies have revealed that bone loss in PMO is closely related to host immunity, which is influenced by the intestinal microbiota. The curative effects of probiotics on metabolic bone diseases have also been demonstrated. The effects of the intestinal microbiota on bone metabolism suggest a promising target for PMO management. This review seeks to summarize the critical effects of the intestinal microbiota and probiotics on PMO, with a focus on the molecular mechanisms underlying the pathogenic relationship between bacteria and host, and to define the possible treatment options.
机译:绝经后骨质疏松症(PMO)是一种以骨骼丢失和结构破坏为特征的普遍代谢性骨病,增加了绝经后妇女骨折的风险。由于PMO的高发病率和严重的并发症,人们已经对其预防和治疗做出了许多努力。肠道微生物群是定居在胃肠道中的复杂的微生物群落。益生菌是由有益的肠道细菌组成的饮食或医学补品,可与内源性肠道微生物协同工作以维持宿主健康。最近的研究表明,PMO中的骨质流失与宿主免疫力密切相关,宿主免疫力受肠道菌群的影响。益生菌对代谢性骨病的治疗效果也已得到证明。肠道菌群对骨代谢的影响表明PMO管理的有希望的目标。这篇综述旨在总结肠道菌群和益生菌对PMO的关键作用,重点关注细菌与宿主之间致病关系的分子机制,并确定可能的治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号